While our in vitro studies indicate that EZH2 inhibition and IFNγ are both required for MHCII upregulation, in vivo the changes seen in the tumor cells may be secondary to immune modulation by EZH2 inhibition. This evidence concerns the gene EZH2 and neoplasm.